.jpg)
Remote patient monitoring (RPM) has been generating strong clinical interest for years, but many practices have been slower to act than the evidence might suggest. The hesitations are familiar: Will patients actually use the devices? Will they transmit data consistently enough for the program to be worth running? Is the administrative lift worth the reimbursement? Those are reasonable questions, and the answers have been getting clearer.
A new retrospective cohort analysis, performed by our team at Prevounce, of 655 patients with stage 1 or stage 2 hypertension enrolled in an RPM program — using cellular-connected blood pressure monitors paired with structured virtual care management — found significant and sustained blood pressure reductions at 3, 6, and 9 months. The results add to a growing body of clinical evidence for RPM in hypertension management, and one finding in particular speaks directly to the compliance concerns that hold practices back.
What the data showed
At nine months, the full cohort of patients who completed participation showed a 6.3% reduction in systolic blood pressure (SBP), 7.4% in diastolic blood pressure (DBP), and 7.0% in mean arterial pressure (MAP) — with improvements sustained at each interval. Results were statistically significant across both age groups studied, under 65 and 65 and older.
Stage 2 patients saw the largest reductions: 9.1% in SBP, 9.7% in DBP, 9.5% in MAP. That tracks with what you'd expect clinically — more uncontrolled blood pressure means more room to move. Stage 1 patients also showed meaningful reductions, which matters for a different reason: patients already near target are often the ones most likely to drift back out of range between office visits, and the data suggests RPM helps hold those gains.
To put the numbers in perspective: a large individual participant-level meta-analysis of 48 randomized trials found that each 5 mmHg reduction in SBP corresponds to roughly a 10% lower risk of major cardiovascular events. The reductions observed here, especially in stage 2 patients, carry real downstream cardiovascular implications.
The finding worth paying attention to
One of the most common reasons practices hesitate on RPM is the worry that patients won't transmit data consistently. Medicare billing for CPT 99454 — the device supply code — has traditionally required 16 or more days of data per month, and providers often wonder whether their patient population will reliably get there. For 2026, CMS addressed part of this concern by finalizing CPT 99445, a new device supply code that covers patients who transmit data for 2 to 15 days in a 30-day period, reimbursed at the same rate as 99454.
The cohort analysis provides the clinical context for why that policy change matters. When patients were split by engagement level — moderate (2 to 15 days of data per month) versus high (16 or more days) — moderate engagement patients achieved a 6.6% MAP reduction at nine months. High engagement patients achieved 7.1%. The gap is narrow.
Care managers provide coaching, education, and escalation when readings trend in the wrong direction. Those interactions appear to carry significant clinical weight regardless of how many monitoring days accumulate. Patients who miss some readings are still having their data reviewed, still receiving guidance, still getting escalated when something looks off. The analysis found patients who transmitted fewer readings showed clinically significant results.
What this means for your practice
For practices evaluating whether to launch or expand an RPM program for hypertensive patients, a few things stand out from these findings.
Stage 2 patients are where the clinical case is strongest. They see the largest absolute reductions, and they carry the highest cardiovascular risk going in. If you're deciding where to start with RPM enrollment, the data points clearly in their direction.
Patient selection shouldn't hinge on whether someone will hit 16 days of readings. The moderate engagement findings, combined with the addition of CPT 99445, mean that a patient who transmits 10 days a month can benefit substantially from a well-run program — and generate reimbursement for the practice. Passing over patients because they seem like they might not be perfectly compliant is likely leaving clinical value and revenue on the table.
Stage 1 patients are worth considering too. The clinical argument here is about preventing deterioration — keeping a patient who is near goal from trending in the wrong direction over months of limited provider contact. It's a quieter benefit than a 9% SBP reduction, but for a population with real cardiovascular risk, it's a meaningful one.
Finally, the outcomes in this analysis came from a program pairing continuous monitoring with structured, recurring human contact. Care managers reviewed incoming data, provided suggestions for lifestyle changes, and escalated to providers when readings warranted it. RPM hardware deployed without that support infrastructure is a different intervention, and worth keeping in mind when evaluating vendors or designing programs.
The bottom line
Hypertension is one of the most undertreated conditions in primary care, and the gap between office visits is a big part of why. This analysis adds to the evidence that RPM paired with structured care management can close that gap in ways that show up in outcomes. The 2026 reimbursement changes make the financial case easier to make alongside the clinical one.
The clinical and financial case for RPM in hypertension is strongest when continuous monitoring is paired with structured care management. Prevounce provides the devices, care management support, and billing infrastructure to run an RPM program that produced these outcomes.
Book a consultation with an expert to see how Prevounce can support your hypertensive population.
* Disclaimer: The above information is for informational purposes only and does not constitute legal, medical, or other professional advice. Billing and coding requirements — especially in the telehealth space — can change and be reinterpreted often. You should always consult an attorney and/or medical billing professional prior to submitting claims for services to ensure that all requirements are met.